Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00126828
Other study ID # LU-11-0031 / 17141
Secondary ID PCRP-07
Status Completed
Phase Phase 1/Phase 2
First received August 3, 2005
Last updated February 23, 2016
Start date January 2003
Est. completion date October 2007

Study information

Verified date October 2011
Source AHS Cancer Control Alberta
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Patients who have limited stage small cell lung cancer are presently treated with chemotherapy and radiation therapy (RT). Despite this aggressive treatment the vast majority of patients will have their cancer recur after treatment. A recurrence is not curable at this time, therefore efforts to reduce recurrence rates are desirable. Due to the sensitivity of surrounding structures in the chest to radiation, it has not been possible to give doses that can cure most tumours. Three-dimensional conformal radiotherapy is a special form of radiation therapy that allows doctors to reduce the amount of radiation dose to normal tissues and therefore reduce toxicity and in turn, let them safely increase the dose to tumours. The purpose of this study is to determine whether the combination of three-dimensional conformal radiotherapy and chemotherapy will be a more effective treatment. If the treatment is found to be safe for the first group of patients, then the total radiation dose will be increased for the next group of patients who are treated on this study.


Description:

Radiotherapy represents one of the primary treatment modalities for patients with limited stage small cell lung cancer (SCLC). With contemporary concurrent radiotherapy and chemotherapy, approximately 20% of patients survive 5 years. While distant metastases are common, local (intrathoracic) failures are common as well, occurring in 40% of treated patients. Reducing local failure rates may lead to improved survival for these patients. There appears a growing body of data, which suggests a radiation dose response relationship for SCLC. However, the close proximity of critical normal structures, such as the spinal cord and esophagus, to the primary tumour limits the prescription dose in conventional radiotherapy. Three Dimensional Conformal Radiotherapy (3DCRT) offers the possibility of reducing normal tissue irradiation and hence reducing the treatment toxicity while maintaining the dose of radiation to the tumour. Another strategy is accelerated fractionation, which shortens the treatment time by allowing less opportunity for tumour cell repopulation. The use of 3DCRT with larger radiation fraction size should maintain satisfactory treatment related toxicity while permitting the potential gains of accelerated fractionation and dose escalation. In this study, patients with limited stage SCLC who are eligible will be treated with a large field (low dose) radiotherapy followed by accelerated 3DCRT given concurrently with standard Cisplatin Etoposide chemotherapy.

Primary Objective: To determine the maximum tolerable dose of radiotherapy for SCLC

Secondary Objectives:

1. To assess treatment toxicity

2. To assess quality of life and retention of pulmonary function

3. To assess progression-free survival on this regimen

Schema: Eligible patients will receive 4 cycles of Cisplatin Etoposide chemotherapy. Thoracic radiotherapy will be given concurrently starting with cycle #2 of chemotherapy. Only one dose level will be open at a time. Four dose levels are planned all delivered in 25 fractions once daily over 5 weeks:

1. 50 Gy (2 Gy per fraction),

2. 58 Gy,

3. 62 Gy,

4. 65 Gy. Patients, who achieve a complete response at the end of chemotherapy and thoracic radiotherapy, will receive prophylactic cranial irradiation.

Evaluation and Follow-up: Patients will be assessed and evaluated at least weekly during radiation therapy. Following treatment, patients will be seen 1 month after the completion of treatment, then every 3 months until 2 years, then every 6 months. Chest x-rays will be performed at each follow-up. CT scan of chest and pulmonary function tests will be performed every 6 months for the first 2 years, then yearly.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date October 2007
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically proven small cell lung cancer

- Age equal to or greater than 18 years

- Good performance status

- Signed study consent form

Exclusion Criteria:

- Patients who have undergone resection

- Wrong histology

- Previous thoracic/neck radiotherapy

- Prior chemotherapy

- Previous ME within 6 months

- Pregnant

- Tumour too large to irradiate safely

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
External beam radiotherapy


Locations

Country Name City State
Canada Cross Cancer Institute Edmonton Alberta

Sponsors (2)

Lead Sponsor Collaborator
AHS Cancer Control Alberta Cross Cancer Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary grade 3 RT toxicity rate
Secondary disease free
Secondary overall survival
See also
  Status Clinical Trial Phase
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00046787 - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT03554473 - M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Phase 1/Phase 2
Terminated NCT00094978 - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum Phase 1
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Completed NCT03092739 - A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
Completed NCT00305942 - Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Terminated NCT00324558 - Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) Phase 2
Completed NCT00359359 - A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer Phase 1/Phase 2
Completed NCT00191750 - A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting NCT02366741 - Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study N/A
Active, not recruiting NCT01900951 - Temozolomide as Maintenance Therapy in Small Cell Lung Cancer Phase 2
Completed NCT00826644 - Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Phase 3
Completed NCT00284154 - Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Phase 2
Recruiting NCT00100256 - Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy Phase 1/Phase 2
Terminated NCT02034123 - Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma Phase 1
Recruiting NCT05500391 - Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Phase 2
Recruiting NCT02688036 - Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC Phase 3